- Home
- ATAI vs ITOS Comparison
ATAI vs ITOS Comparison
Compare ATAI & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- ITOS
- Stock Information
- Founded
- ATAI 2018
- ITOS 2011
- Country
- ATAI Germany
- ITOS United States
- Employees
- ATAI N/A
- ITOS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATAI Health Care
- ITOS Health Care
- Exchange
- ATAI Nasdaq
- ITOS Nasdaq
- Market Cap
- ATAI 271.6M
- ITOS 270.7M
- IPO Year
- ATAI 2021
- ITOS 2020
- Fundamental
- Price
- ATAI $1.52
- ITOS $6.43
- Analyst Decision
- ATAI Strong Buy
- ITOS Strong Buy
- Analyst Count
- ATAI 4
- ITOS 3
- Target Price
- ATAI $9.00
- ITOS $26.00
- AVG Volume (30 Days)
- ATAI 1.8M
- ITOS 396.2K
- Earning Date
- ATAI 03-17-2025
- ITOS 03-05-2025
- Dividend Yield
- ATAI N/A
- ITOS N/A
- EPS Growth
- ATAI N/A
- ITOS N/A
- EPS
- ATAI N/A
- ITOS N/A
- Revenue
- ATAI $308,000.00
- ITOS $35,000,000.00
- Revenue This Year
- ATAI N/A
- ITOS N/A
- Revenue Next Year
- ATAI $20.00
- ITOS $121.70
- P/E Ratio
- ATAI N/A
- ITOS N/A
- Revenue Growth
- ATAI N/A
- ITOS 177.89
- 52 Week Low
- ATAI $0.78
- ITOS $6.40
- 52 Week High
- ATAI $2.85
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- ATAI 50.35
- ITOS 39.03
- Support Level
- ATAI $1.37
- ITOS $6.72
- Resistance Level
- ATAI $1.48
- ITOS $7.05
- Average True Range (ATR)
- ATAI 0.10
- ITOS 0.32
- MACD
- ATAI 0.02
- ITOS -0.03
- Stochastic Oscillator
- ATAI 79.71
- ITOS 1.61
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.